Cell Gene Editing

Although gene edited animal models are very powerful tools for biomedical research, cell lines have many advantages including convenience, fast timeline, and low cost.

Our gene editing services for cell lines include free preliminary evaluation experiments, single cell colonization, genotyping and validation, tumor formation experiments, and FACS analysis.

Application Example #1:

A knockin cell line model was generated with EGFP inserted at the translation initiation site of ACTB (cytoskeleton filiform protein) in the U2OS cell line (human osteosarcoma). 

ACTB gene encodes β-actin, a cytoskeletal protein. The homologous arms of the targeting vector are about 1 kb, and the homologous recombination of target vector was done by CRISPR/cas9 based EGE™ technology.

A similar gene editing strategy was used for LMNB1, which encodes the nucleoprotein Lamin-B1.

In U2OS cells, flow cytometry plots show that the efficiency of EGFP-ACTB gene knockin mediated by EGE™ (15.02%) is 8 times higher compared to CRISPR/Cas9-mediated knockin (1.91%). In the C6 cell line, the EGE™ system improves the knockin efficiency of EGFP-LMNB1 to 3.6% from 0.19%, which is a 19-fold increase.

Application Example #2:

Gene editing of hESCs and iPSCs

The highly efficient EGE™ system is ideal for editing the genomes of induced pluripotent stem cells (iPSCs) and human embryonic stem cells (hESCs) . 

Multiple iPSC lines are reprogrammed from human fibroblasts by non-integrated plasmids. Panel A shows phase contrast images. This iPSC line expresses the pluripotency markers OCT4, SSEA-4 and TRA-1-60 as shown in Panel B and have a normal karyotype (Panel C) . Teratoma forms in immunodeficient mice (Panel D).

Human-Pluripotent-Stem-Cell

Humanized Tumor Cell Lines

Product BCG No. Organism Disease Culture Property
B-CAG-hCD155 LLC1 Cell Line B-MCL-017 Murine lewis lung carcinoma mixed, adherent and suspension
B-CAG-hCD155 MC38 Cell Line B-MCL-016 Murine colorectal cancer adherent
B-CAG-hCD47 MC38 Cell Line B-MCL-014 Murine colorectal cancer adherent
B-CAG-hCEACAM1 LLC1 Cell Line B-MCL-011 Murine lewis lung carcinoma mixed, adherent and suspension
B-CAG-hCEACAM1 MC38 Cell Line B-MCL-009 Murine colorectal cancer adherent
B-CAG-hCLDN18.2 MC38 Cell Line B-MCL-042 Murine colorectal cancer adherent
B-CAG-hHER2 MC38 Cell Line B-MCL-022 Murine colorectal cancer adherent
B-CAG-hHVEM LLC1 Cell Line B-MCL-013 Murine lewis lung carcinoma mixed, adherent and suspension
B-CAG-hHVEM MC38 Cell Line B-MCL-012 Murine colorectal cancer adherent
B-CAG-hPD-L1 B16-F10 Cell Line B-MCL-006 Murine melanoma adherent
B-CAG-hPD-L1 CCRF S-180II Cell Line B-MCL-008 Murine sarcoma adherent
B-CAG-hPD-L1 Hepa 1-6 Cell Line B-MCL-007 Murine hepatoma adherent
B-CAG-hPD-L1 LLC1 Cell Line B-MCL-005 Murine lewis lung carcinoma mixed, adherent and suspension
B-CAG-hPD-L1 MC38 Cell Line B-MCL-004 Murine colorectal cancer adherent
B-CAG-hPD-L1 MC38 Cell Line (v2) B-MCL-018 Murine colorectal cancer adherent
B-CAG-hPD-L1(v2)/hCD47 MC38 Cell Line B-MCL-040 Murine colorectal cancer adherent
B-CAG-hPD-L2 MC38 Cell Line B-MCL-024 Murine colorectal cancer adherent
B-hCD47 CT26.WT Cell Line B-MCL-023 Murine colorectal cancer adherent
B-hCD47 MC38 Cell Line (v2) B-MCL-015 Murine colorectal cancer adherent

Luciferase Reporter Tumor Cell Lines

Product Disease Organism Culture Type
B-Luciferase 4T1 Cell Line Breast carcinoma Murine Adherent
B-Luciferase B16-F10 Cell Line Melanoma Murine Adherent
B-Luciferase EL4 Cell Line Lymphoma Mouse Suspension
B-Luciferase Hep3B2.1-7 Cell Line Hepatocellular carcinoma Human Adherent
B-Luciferase Hepa 1-6 Cell Line Hepatoma Mouse Adherent
B-Luciferase K562 Cell Line Leukemia (CML) Human Suspension
B-Luciferase MIA PaCa-2 Cell Line Pancreatic carcinoma Human Adherent
B-Luciferase U87-MG Cell Line Glioblastoma Human Adherent
B-Luciferase-GFP HT-29 Cell Line Colorectal adenocarcinoma Human Adherent
B-Luciferase-GFP NCI-H1975 Cell Line Adenocarcinoma; non­small cell lung cancer Human Adherent
B-Luciferase-GFP Raji Cell Line Lymphoma, Burkitt’s Human Suspension
Back to top